ACT1

ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen and Lapatinib in breast cancer. ACT1 can be used for breast cancer research .


Cat. No.: EX-A17265	Purity: >98%

	Chemical structure of ACT1

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	895547-36-1
Purity	>98%
Formula	C150H238N48O34
Mol Weight	3257.796
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Grek CL, et al. Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 3;15:296.
CoA	CoA of ACT1

Smiles:	C([C@H](NC(=O)[C@H]1N(C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]2N(C([C@@H](NC([C@H](CC=3C=4C(NC3)=CC=CC4)NC([C@@H](NC([C@@H](NC(=O)[C@H]5N(C([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)CCC5)CCCCN)=O)[C@H](CC)C)=O)=O)CC6=CC=CC=C6)=O)CCC2)CC(N)=O)=


		Search